Nothing to do with the drug, but it has everything to do with how the company treats it's shareholders:
According to SEC filings, almost $20M in total compensation to ONE individual, the CEO of AVXL, using cash and options issued from the company (over the past 4 years).
No transaction with other individuals noted in the filings.
I believe that Missling's objective is to keep the gravy train running as long as possible... Move to another country, introduce multi-year running trials without control protocols, mix in some hopeful possibilities, and keep that train running...